<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p195" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_195{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_195{left:306px;bottom:30px;}
#t3_195{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_195{left:346px;bottom:30px;}
#t5_195{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_195{left:517px;bottom:30px;}
#t7_195{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_195{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_195{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_195{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_195{left:35px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#tc_195{left:104px;bottom:777px;}
#td_195{left:121px;bottom:777px;letter-spacing:0.14px;word-spacing:0.05px;}
#te_195{left:35px;bottom:754px;letter-spacing:0.29px;}
#tf_195{left:84px;bottom:761px;letter-spacing:-0.01px;}
#tg_195{left:35px;bottom:713px;letter-spacing:0.02px;word-spacing:0.17px;}
#th_195{left:35px;bottom:690px;letter-spacing:0.12px;word-spacing:-0.72px;}
#ti_195{left:35px;bottom:667px;letter-spacing:0.12px;word-spacing:0.07px;}
#tj_195{left:35px;bottom:645px;letter-spacing:0.11px;word-spacing:0.08px;}
#tk_195{left:392px;bottom:653px;letter-spacing:0.1px;}
#tl_195{left:438px;bottom:645px;letter-spacing:-0.07px;word-spacing:0.26px;}
#tm_195{left:35px;bottom:622px;letter-spacing:0.13px;word-spacing:0.06px;}
#tn_195{left:389px;bottom:629px;letter-spacing:-0.01px;}
#to_195{left:412px;bottom:622px;letter-spacing:0.2px;word-spacing:-0.02px;}
#tp_195{left:35px;bottom:599px;letter-spacing:0.07px;}
#tq_195{left:156px;bottom:606px;letter-spacing:-0.01px;}
#tr_195{left:178px;bottom:599px;letter-spacing:0.08px;word-spacing:-0.09px;}
#ts_195{left:35px;bottom:575px;letter-spacing:0.06px;word-spacing:0.13px;}
#tt_195{left:35px;bottom:552px;letter-spacing:0.15px;word-spacing:0.04px;}
#tu_195{left:35px;bottom:529px;letter-spacing:0.08px;word-spacing:-0.62px;}
#tv_195{left:35px;bottom:506px;letter-spacing:0.06px;word-spacing:0.13px;}
#tw_195{left:35px;bottom:482px;letter-spacing:0.1px;word-spacing:0.08px;}
#tx_195{left:35px;bottom:459px;letter-spacing:0.12px;word-spacing:0.06px;}
#ty_195{left:35px;bottom:436px;letter-spacing:0.07px;word-spacing:-0.98px;}
#tz_195{left:35px;bottom:413px;letter-spacing:0.09px;word-spacing:0.09px;}
#t10_195{left:35px;bottom:390px;letter-spacing:0.14px;word-spacing:0.05px;}
#t11_195{left:35px;bottom:366px;letter-spacing:0.08px;word-spacing:-1.13px;}
#t12_195{left:35px;bottom:343px;letter-spacing:0.17px;word-spacing:0.01px;}
#t13_195{left:35px;bottom:320px;letter-spacing:0.11px;word-spacing:0.08px;}
#t14_195{left:35px;bottom:297px;letter-spacing:0.08px;word-spacing:-0.64px;}
#t15_195{left:35px;bottom:273px;letter-spacing:0.05px;word-spacing:0.14px;}
#t16_195{left:540px;bottom:281px;letter-spacing:-0.01px;}
#t17_195{left:35px;bottom:250px;letter-spacing:0.15px;word-spacing:0.04px;}
#t18_195{left:35px;bottom:227px;letter-spacing:0.13px;word-spacing:0.06px;}
#t19_195{left:35px;bottom:204px;letter-spacing:0.14px;word-spacing:-0.74px;}
#t1a_195{left:35px;bottom:181px;letter-spacing:0.09px;word-spacing:-0.77px;}
#t1b_195{left:35px;bottom:157px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1c_195{left:496px;bottom:165px;letter-spacing:-0.01px;}
#t1d_195{left:519px;bottom:157px;letter-spacing:-0.07px;word-spacing:0.25px;}
#t1e_195{left:35px;bottom:134px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1f_195{left:35px;bottom:111px;letter-spacing:0.08px;word-spacing:-0.76px;}
#t1g_195{left:35px;bottom:88px;letter-spacing:0.08px;}
#t1h_195{left:618px;bottom:775px;letter-spacing:-0.25px;word-spacing:3.15px;}
#t1i_195{left:618px;bottom:746px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1j_195{left:618px;bottom:723px;letter-spacing:0.01px;word-spacing:0.17px;}
#t1k_195{left:618px;bottom:700px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1l_195{left:618px;bottom:677px;letter-spacing:0.11px;word-spacing:-1.16px;}
#t1m_195{left:618px;bottom:654px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1n_195{left:618px;bottom:630px;letter-spacing:0.07px;word-spacing:-0.75px;}
#t1o_195{left:618px;bottom:607px;letter-spacing:0.04px;word-spacing:-0.76px;}
#t1p_195{left:618px;bottom:584px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1q_195{left:618px;bottom:561px;letter-spacing:0.13px;word-spacing:-0.68px;}
#t1r_195{left:618px;bottom:537px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1s_195{left:618px;bottom:514px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1t_195{left:618px;bottom:491px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1u_195{left:618px;bottom:452px;letter-spacing:0.17px;}
#t1v_195{left:618px;bottom:423px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1w_195{left:618px;bottom:399px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1x_195{left:618px;bottom:376px;letter-spacing:0.02px;word-spacing:0.27px;}
#t1y_195{left:618px;bottom:353px;letter-spacing:0.01px;word-spacing:0.29px;}
#t1z_195{left:618px;bottom:330px;letter-spacing:0.05px;word-spacing:-0.72px;}
#t20_195{left:618px;bottom:306px;letter-spacing:0.01px;word-spacing:-0.69px;}
#t21_195{left:618px;bottom:283px;letter-spacing:0.09px;word-spacing:0.09px;}
#t22_195{left:618px;bottom:260px;letter-spacing:0.18px;word-spacing:0.01px;}
#t23_195{left:618px;bottom:237px;letter-spacing:0.15px;word-spacing:0.04px;}
#t24_195{left:618px;bottom:214px;word-spacing:0.19px;}
#t25_195{left:618px;bottom:190px;letter-spacing:0.17px;word-spacing:0.02px;}
#t26_195{left:618px;bottom:150px;letter-spacing:0.07px;word-spacing:-0.13px;}
#t27_195{left:618px;bottom:128px;letter-spacing:0.12px;word-spacing:0.06px;}
#t28_195{left:618px;bottom:105px;letter-spacing:0.09px;word-spacing:0.09px;}
#t29_195{left:618px;bottom:82px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2a_195{left:618px;bottom:58px;letter-spacing:0.05px;word-spacing:0.13px;}
#t2b_195{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_195{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_195{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_195{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_195{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_195{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_195{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_195{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_195{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s8_195{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts195" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg195Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg195" style="-webkit-user-select: none;"><object width="1210" height="935" data="195/195.svg" type="image/svg+xml" id="pdf195" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_195" class="t s0_195">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_195" class="t s1_195">© </span>
<span id="t3_195" class="t s0_195">(NCCN </span>
<span id="t4_195" class="t s1_195">© </span>
<span id="t5_195" class="t s0_195">), All rights reserved. NCCN Guidelines </span>
<span id="t6_195" class="t s1_195">® </span>
<span id="t7_195" class="t s0_195">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_195" class="t s2_195">NCCN Guidelines Version 4.2024 </span>
<span id="t9_195" class="t s2_195">Head and Neck Cancers </span>
<span id="ta_195" class="t s3_195">MS-54 </span>
<span id="tb_195" class="t s4_195">therapy (</span><span id="tc_195" class="t s5_195">N </span><span id="td_195" class="t s4_195">= 121) showed comparable response rates between the two </span>
<span id="te_195" class="t s4_195">drugs. </span>
<span id="tf_195" class="t s6_195">676 </span>
<span id="tg_195" class="t s4_195">The panel recommends immunotherapy (nivolumab and pembrolizumab) </span>
<span id="th_195" class="t s4_195">as the category 1 preferred option for patients with recurrent or metastatic </span>
<span id="ti_195" class="t s4_195">SCCHN who have progressed on or following platinum-based </span>
<span id="tj_195" class="t s4_195">chemotherapy based on high-quality evidence. </span>
<span id="tk_195" class="t s6_195">637,638 </span>
<span id="tl_195" class="t s4_195">Pembrolizumab is </span>
<span id="tm_195" class="t s4_195">also an option for treatment of MSI-H disease. </span>
<span id="tn_195" class="t s6_195">673 </span>
<span id="to_195" class="t s4_195">Based on results from </span>
<span id="tp_195" class="t s4_195">KEYNOTE-158, </span>
<span id="tq_195" class="t s6_195">558 </span>
<span id="tr_195" class="t s4_195">pembrolizumab is also FDA-approved for patients with </span>
<span id="ts_195" class="t s4_195">previously treated TMB-H unresectable or metastatic disease that has </span>
<span id="tt_195" class="t s4_195">progressed following prior treatment with no satisfactory treatment </span>
<span id="tu_195" class="t s4_195">alternatives. Even though the basket trial contained no patients with TMB- </span>
<span id="tv_195" class="t s4_195">H SCCHN, the panel has included pembrolizumab for TMB-H disease as </span>
<span id="tw_195" class="t s4_195">an option for patients with recurrent or metastatic SCCHN based on the </span>
<span id="tx_195" class="t s4_195">FDA approval. Despite the ambiguities of PD-L1 testing and definitions, </span>
<span id="ty_195" class="t s4_195">PD-L1 expression may be associated with better outcomes from treatment </span>
<span id="tz_195" class="t s4_195">with immunotherapy for recurrent or metastatic SCCHN (ie, greater </span>
<span id="t10_195" class="t s4_195">likelihood of response to pembrolizumab and greater survival benefit in </span>
<span id="t11_195" class="t s4_195">response to nivolumab). The panel included fam-trastuzumab deruxtecan- </span>
<span id="t12_195" class="t s4_195">nxki for HER2-positive disease (in the subsequent line setting with no </span>
<span id="t13_195" class="t s4_195">satisfactory alternative treatment options) based on the 2024 FDA </span>
<span id="t14_195" class="t s4_195">approval for all solid tumors. However, the DESTINY-PanTumor02 basket </span>
<span id="t15_195" class="t s4_195">trial included &lt;5 patients with non-salivary head and neck cancers. </span>
<span id="t16_195" class="t s6_195">677 </span>
<span id="t17_195" class="t s4_195">Therefore, this is a category 2B option based on less panel consensus. </span>
<span id="t18_195" class="t s4_195">For all other systemic therapy options recommended by the panel, there </span>
<span id="t19_195" class="t s4_195">are no clear advantages of one agent over another in the subsequent-line </span>
<span id="t1a_195" class="t s4_195">setting, although response rates seem to be highest with taxanes. Afatinib </span>
<span id="t1b_195" class="t s4_195">has a PFS benefit, but not an OS benefit, over methotrexate </span>
<span id="t1c_195" class="t s6_195">675 </span>
<span id="t1d_195" class="t s4_195">and is a </span>
<span id="t1e_195" class="t s4_195">category 2B systemic therapy option for non-nasopharyngeal persistent </span>
<span id="t1f_195" class="t s4_195">H&amp;N cancer or cancer that has progressed on or after platinum-containing </span>
<span id="t1g_195" class="t s4_195">chemotherapy. </span>
<span id="t1h_195" class="t s7_195">Occult Primary Cancer </span>
<span id="t1i_195" class="t s4_195">Occult or unknown primary H&amp;N cancer is defined as metastatic </span>
<span id="t1j_195" class="t s4_195">carcinoma in a cervical lymph node without an identifiable primary site </span>
<span id="t1k_195" class="t s4_195">after appropriate investigation. This is an uncommon disease entity, </span>
<span id="t1l_195" class="t s4_195">accounting for approximately 5% of patients presenting to referral centers. </span>
<span id="t1m_195" class="t s4_195">The most frequent histology is squamous cell carcinoma. Although </span>
<span id="t1n_195" class="t s4_195">patients with very small tonsil and tongue base cancers frequently present </span>
<span id="t1o_195" class="t s4_195">with enlarged neck nodes and are initially classified as having an unknown </span>
<span id="t1p_195" class="t s4_195">primary, most will eventually be diagnosed by directed biopsy and </span>
<span id="t1q_195" class="t s4_195">tonsillectomy. The emergence of the primary site after therapy and during </span>
<span id="t1r_195" class="t s4_195">follow up is rare. H&amp;N cancer of unknown primary site is a highly curable </span>
<span id="t1s_195" class="t s4_195">disease. After appropriate evaluation and treatment, most patients </span>
<span id="t1t_195" class="t s4_195">experience low morbidity and long-term disease control. </span>
<span id="t1u_195" class="t s3_195">Workup </span>
<span id="t1v_195" class="t s4_195">The majority of patients &gt;40 years of age who present with a neck mass </span>
<span id="t1w_195" class="t s4_195">prove to have malignant lymph node involvement. In situations where </span>
<span id="t1x_195" class="t s4_195">metastatic carcinoma is found in cervical lymph nodes, the primary site is </span>
<span id="t1y_195" class="t s4_195">almost always discovered in the course of a complete H&amp;N examination </span>
<span id="t1z_195" class="t s4_195">and imaging evaluation. FNA is the preferred diagnostic procedure when a </span>
<span id="t20_195" class="t s4_195">malignant cervical lymph node is suspected. FNA obtained from cystic and </span>
<span id="t21_195" class="t s4_195">necrotic lymph nodes may be non-diagnostic, and, in these situations, a </span>
<span id="t22_195" class="t s4_195">core biopsy may be obtained. Open biopsy should not be performed </span>
<span id="t23_195" class="t s4_195">unless the patient is prepared for definitive surgical management of the </span>
<span id="t24_195" class="t s4_195">malignancy, which may entail a neck dissection, and patients should be </span>
<span id="t25_195" class="t s4_195">counseled accordingly in the preoperative period. </span>
<span id="t26_195" class="t s4_195">Patients with a biopsy-proven carcinoma of a cervical lymph node require </span>
<span id="t27_195" class="t s4_195">a thorough history with emphasis on tobacco exposure, prior cancer </span>
<span id="t28_195" class="t s4_195">history, including previous resected early-stage cutaneous malignancies, </span>
<span id="t29_195" class="t s4_195">and ethnic descent from endemic NPC regions. A physical examination </span>
<span id="t2a_195" class="t s4_195">documenting cervical lymph node levels may inform potential primary </span>
<span id="t2b_195" class="t s8_195">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
